|By Marketwired .||
|February 1, 2013 10:57 AM EST||
SAN FRANCISCO, CA -- (Marketwire) -- 02/01/13 -- Life sciences financing activity got a strong start in the new year as companies raised $10.3 billion in January. The Pfizer animal health unit Zoetis was responsible for more than half the activity through a debt offering and the largest IPO since Facebook debuted in May 2012. The robust activity dwarfed the $4.2 billion raised during the same period a year ago, according to Burrill & Company.
Companies raised more than $6 billion during the month through debt offerings. This included Zoetis' heavily oversubscribed $3.7 billion bond deal ahead of its IPO. It also included nearly $1.3 billion in debt offerings from nine smaller therapeutics companies, as well as nearly $700 million raised in two medical device company financings.
The Zoetis IPO priced at $26, above its expected $22 to $25 range. Three other companies, LipoScience, an in vitro diagnostic company; Stemline Therapeutics, which is developing therapies that target cancer stem cells; and KaloBios Pharmaceuticals, a developer of next-generation antibodies, raised a combined $153 million through initial public offerings. That compares to $135 million raised through IPOs on U.S. exchanges a year ago. Almost $1.6 billion was raised by follow-ons in January, tripling January 2012's total, and reflecting the improved environment for public therapeutics companies seeking to raise capital.
"Enthusiasm in the market for life sciences has picked up following a positive JPMorgan Healthcare Conference, a strong year of FDA approvals capped with a flurry of activity in December, and the impressive returns the sector provided in 2012," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused exclusively on the life sciences. "Though the activity is encouraging, capital continues to be expensive and difficult to access for many companies, particularly those that have not yet commercialized products."
BURILL INDICES Month Year Index 12/31/2012 1/31/2013 Change Change Burrill Select 607.66 634.23 4.4% 4.4% Burrill Large Cap 736.90 759.90 3.1% 3.1% Burrill Mid-Cap 309.52 332.44 7.4% 7.4% Burrill Small Cap 105.99 119.39 12.6% 12.6% Burrill Diagnostics 191.32 202.54 5.9% 5.9% Burrill Personalized Medicine 119.22 127.48 6.9% 6.9% Burrill Biogreentech 162.27 175.67 8.3% 8.3% NASDAQ 3019.51 3142.13 4.1% 4.1% DJIA 13104.14 13860.58 5.8% 5.8% S&P 500 1426.19 1498.11 5.0% 5.0% Amex Biotech 1547.03 1661.17 7.4% 7.4% Amex Pharmaceutical 369.57 394.99 6.9% 6.9%
On the venture capital front, life sciences companies globally raised nearly $1.1 million in January, about the same as a year ago. That included the $294 million investment in Brazil-based GraalBio, which will use the funding to develop cellulosic ethanol technologies at its first commercial facility located in Alagoas, Brazil. The $709 million raised by U.S.-based companies in January, though, is down about 14 percent from activity a year ago.
Global M&A activity for January reached $4.5 billion, down 32 percent from a year ago. Botox-maker Allergan's $958 million acquisition of MAP Pharmaceuticals, its partner in developing the experimental orally-inhaled migraine drug Levadex, was the largest transaction for the month. The acquisition reflects an effort by Allergan to expand its offerings to neurologists and pain specialists. The U.S. Food and Drug Administration is expected to decide on whether it will approve Levadex in April.
Global partnering deals fell to $2.1 billion in January, a 56 percent decline from levels a year ago. Gilead Sciences' collaboration with MacroGenics -- worth up to $1.1 billion -- covers the development and commercialization of bi-specific antibodies directed at four undisclosed targets chosen by Gilead. The biotech's proprietary Dual Affinity Re-Targeting platform, or DART, can engineer antibodies that can target multiple antigens, an area of growing interest among drug developers as they seek to increase the efficacy of their therapies by hitting multiple targets at the same time.
"The low numbers for partnering activity extend a downturn seen in 2012 in part because of fewer financial terms being disclosed," says Burrill. "But it also reflects a shift among larger pharmaceutical companies focusing more of their attention to academic and non-profit research institutions as they look for discovery- and early-stage candidates."
Life Sciences Scorecard in USD M YTD YTD 1/31/13 1/31/12 Change Global Venture Capital 1,144 1,064 7.5% U.S. VC 795 826 -3.8% IPOs (4 in 2013 vs 3 in 2012) 2,253 262 759.9% U.S. IPOs (4 in 2013 vs 2 in 2012) 2,253 135 1568.9% Global PIPEs 184 158 16.5% U.S. PIPEs 101 72 40.3% Global Follow-ons 1,585 477 232.3% U.S. Follow-ons 1,585 477 232.3% Global Other Equity 54 338 -84.0% U.S. Other Equity 45 323 -86.1% Global Debt Offerings 5,783 2,593 123.0% U.S. Debt 4,968 2,201 125.7% Global Other Debt 263 338 -22.2% U.S. Other Debt 226 334 -32.3% Total Global Public Financings 10,122 4,166 143.0% Total U.S. Public Financings 9,178 3,542 159.1% Global Partnering 2,082 4,713 -55.8% U.S. Partner/Licenser 1,889 2,676 -29.4% Global M&A 4,859 6,720 -27.7% M&A, U.S. Target 2,482 5,765 -56.9%
The FDA in January approved a trio of new drug treatments for type 2 diabetes. All three drugs, Nesina, Kazano, and Oseni will be distributed by Takeda Pharmaceutical and include the new molecular entity alogliptin, developed through a partnership between Takeda and Furiex Pharmaceuticals. Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control. Nesina tablets contain alogliptin alone, while Kazano combines alogliptin with the already-approved metformin hydrochloride and Oseni combines it with pioglitazone.
The agency also approved Kynamro, a new injectable cholesterol-lowering drug co-developed by Genzyme and Isis Pharmaceuticals, despite liver safety concerns. Kynamro, also known as mipomersen, is approved to treat people with homozygous familial hypercholesterolemia, an inherited condition that causes high levels of low-density lipoprotein cholesterol levels beginning at birth, and heart attacks at an early age. The approval comes about one month after Aegerion Pharmaceuticals won U.S. approval for Juxtapid, another medicine for the disorder that comes in pill form.
The European Commission announced the winners of its Future and Emerging Technologies Flagship Initiative, the largest single science competition to be held in Europe to date. Each will receive $1.36 billion (EUR 1 billion) over ten years. The Human Brain Project was named as one of the winners. It will create the world's largest experimental brain research facility and seeks to develop a detailed model of the human brain so researchers can study how it works and ultimately develop personalized treatments for neurological and related diseases.
The California Institute for Regenerative Medicine -- California's stem cell agency backed by a $3 billion ballot initiative -- said its board has adopted a framework of proposals that could "dramatically change some aspects of its work." The proposals are aimed at addressing criticism over potential conflicts of interest in the way the board decides how to allocate grants and come in response to a series of recommendations from the Institute of Medicine. The IOM made those recommendations as part of a report requested by the agency, which was seeking an independent assessment of its programs, operations, strategies, and performance.
"CIRM's funding is expected to last about four more years, but there are many who hope it will have a life that extends well beyond that period," says Burrill. "It's vital that it has credibility and the public's trust if it is to continue its mission far into the future."
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.
Burrill & Company
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Aug. 29, 2016 10:15 PM EDT Reads: 273
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Aug. 29, 2016 10:00 PM EDT Reads: 2,483
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Aug. 29, 2016 08:30 PM EDT Reads: 2,438
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Aug. 29, 2016 07:45 PM EDT Reads: 1,661
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Aug. 29, 2016 07:00 PM EDT Reads: 1,980
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
Aug. 29, 2016 06:15 PM EDT Reads: 320
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Aug. 29, 2016 02:15 PM EDT Reads: 3,745
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Aug. 29, 2016 12:45 PM EDT Reads: 2,028
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Aug. 29, 2016 12:15 PM EDT Reads: 837
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Aug. 29, 2016 12:00 PM EDT Reads: 3,199
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aug. 29, 2016 08:00 AM EDT Reads: 959
Pulzze Systems was happy to participate in such a premier event and thankful to be receiving the winning investment and global network support from G-Startup Worldwide. It is an exciting time for Pulzze to showcase the effectiveness of innovative technologies and enable them to make the world smarter and better. The reputable contest is held to identify promising startups around the globe that are assured to change the world through their innovative products and disruptive technologies. There w...
Aug. 29, 2016 07:30 AM EDT Reads: 824
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Aug. 29, 2016 02:15 AM EDT Reads: 1,846
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Aug. 29, 2016 01:45 AM EDT Reads: 2,208
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Aug. 29, 2016 01:15 AM EDT Reads: 3,038
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Aug. 29, 2016 12:00 AM EDT Reads: 1,925
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Aug. 28, 2016 10:30 PM EDT Reads: 4,079
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Aug. 27, 2016 12:45 PM EDT Reads: 2,412
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
Aug. 27, 2016 02:30 AM EDT Reads: 2,101
Is the ongoing quest for agility in the data center forcing you to evaluate how to be a part of infrastructure automation efforts? As organizations evolve toward bimodal IT operations, they are embracing new service delivery models and leveraging virtualization to increase infrastructure agility. Therefore, the network must evolve in parallel to become equally agile. Read this essential piece of Gartner research for recommendations on achieving greater agility.
Aug. 25, 2016 05:15 PM EDT Reads: 928